Lenvatinib - Eisai Co Ltd

Drug Profile

Lenvatinib - Eisai Co Ltd

Alternative Names: E-7080; ER-203492-00; Kisplyx; Lenvatinib mesylate; Lenvima

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Registered Hepatocellular carcinoma
  • Phase II Biliary cancer; Endometrial cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Thymoma
  • Phase I/II Breast cancer; Solid tumours
  • Phase I Ovarian cancer
  • Discontinued Cancer; Glioma; Lymphoma

Most Recent Events

  • 26 Mar 2018 Eisai plans a phase II trial for Solid tumours in April 2018 , (NCT03477175)
  • 23 Mar 2018 Registered for Hepatocellular carcinoma (First-line therapy, Inoperable/Unresectable) in Japan (PO)
  • 07 Mar 2018 Eisai and Merck agree to co-develop and co-commercialise lenvatinib as monotherapy and in combination with pembrolizumab for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top